19.06.2014
- Canada's Valeant Pharmaceuticals is taking its hostile $50.8 billion bid to acquire Botox manufacturer Allergan directly to shareholders. Backed by activist shareholder Bill Ackman...
13.05.2014
- U.S. drugmaker Allergan has rejected the $47 billion takeover bid of Canada-based Valeant Pharmaceuticals International, saying the suitor's proposed cost cuts of at least $2.7...
03.04.2013
- AstraZeneca boosted its early-stage pipeline of experimental heart drugs on Wednesday by buying privately held U.S. biotechnology company AlphaCore Pharma, which is developing a...
25.03.2013
- Shire is to buy privately owned U.S. biotech firm SARcode Bioscience, paying $160 million upfront to win rights to a new drug in late-stage development for dry eye diseases. The...
18.03.2013
- AstraZeneca is to cut around 1,600 jobs as it overhauls research operations and consolidates drug development work in three major centres in Britain, the United States and Sweden...
18.03.2013
- AstraZeneca's new CEO Pascal Soriot, outlining his investment strategy for the ailing drugmaker this week, is unlikely to offer any quick fixes to plug a looming $6 billion sales...
08.01.2013
- British drugmaker Shire has agreed to buy Lotus Tissue Repair, a U.S. biotechnology company developing the first treatment for a rare genetic disorder that causes extremely fragile...
03.01.2013
- Rare diseases are a growing focus for drug companies, with prices for some treatments for ultra-rare conditions running into hundreds of thousands of dollars a year. The following...
